Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1.

Methods Mol Biol

Faculty of Medicine, Department of Biochemistry, The University of Hong Kong, Pokfulam, Hong Kong, China.

Published: December 2010

The proliferation-associated transcription factor FOXM1 is essential for cell cycle progression into mitosis. Using synchronized human fibroblasts we detected, by immunostaining, that FOXM1 is localized predominantly in the cytoplasm in cells at late-G1 and S phases. Nuclear translocation occurs just before progression into the G2/M phase of the cell cycle and requires activity of the Raf/MEK/MAPK signaling pathway. Using pharmacological modulators, we demonstrated that activity of the Raf/MEK/MAPK pathway is both necessary and sufficient for the nuclear translocation of FOXM1. Consistent with FoxM1c being the major isoform expressed in proliferating fibroblasts, constitutively active MEK1 enhances the transactivating effect of FOXM1c, but not FOXM1b, on the cyclin B1 promoter in transient reporter assays. Here, we describe in detail the methods involved in generating these findings, which support the notion that FOXM1 is an effector of Raf/MEK/MAPK signaling in G2/M regulation.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-60761-738-9_6DOI Listing

Publication Analysis

Top Keywords

raf/mek/mapk signaling
12
nuclear translocation
12
cell cycle
8
activity raf/mek/mapk
8
foxm1
5
raf/mek/mapk
4
signaling stimulates
4
stimulates nuclear
4
translocation transactivating
4
transactivating activity
4

Similar Publications

Parthenolide Inhibits Synthesis and Promotes Degradation of Programmed Cell Death Ligand 1 and Enhances T Cell Tumor-Killing Activity.

J Agric Food Chem

September 2024

Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin Province 133002, China.

Parthenolide is a germacrane sesquiterpene lactone separated from the traditional medicinal plant feverfew. Previous studies have shown that parthenolide possesses many pharmacological activities, involving anti-inflammatory and anticancer activities. However, the antitumor mechanism of parthenolide has not been fully elucidated.

View Article and Find Full Text PDF

Non-canonical variants and rearrangements in hairy cell leukemia.

Oncol Res

September 2024

Cancer Molecular Diagnostics, St. James's Hospital, Dublin, D08 W9RT, Ireland.

Article Synopsis
  • * Most HCL patients have the V600E mutation, making it a key target for treating those who don't respond to standard therapies, but some may have different mutations.
  • * Diagnosing HCL patients without the V600E mutation requires careful evaluation for other genetic changes, which could reveal new insights into the disease and improve targeted treatment options.
View Article and Find Full Text PDF
Article Synopsis
  • Canine oral squamous cell carcinoma (COSCC) is a common and aggressive oral tumor in dogs, with a significant risk of metastasis at diagnosis.
  • The typical treatment involves wide surgical excision, which can have a considerable impact on a dog's quality of life.
  • Recent research shows that the MEK inhibitor trametinib, an FDA-approved drug for human cancers, effectively reduces COSCC cell growth and may lead to tumor regression in some canine patients, offering new hope for better treatment options.
View Article and Find Full Text PDF

Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.

Adv Cancer Res

June 2023

Department of Surgery, Division of Surgical Oncology, the University of Illinois at Chicago, Chicago, IL, United States; University of Illinois Hospital & Health Sciences System Cancer Center, the University of Illinois at Chicago, Chicago, IL, United States; Jesse Brown VA Medical Center, Chicago, IL, United States. Electronic address:

Pancreatic Ductal Adenocarcinoma (PDAC), commonly called pancreatic cancer, is aggressive cancer usually detected at a late stage, limiting treatment options with modest clinical responses. It is projected that by 2030, PDAC will be the second most common cause of cancer-related mortality in the United States. Drug resistance in PDAC is common and significantly affects patients' overall survival (OS).

View Article and Find Full Text PDF

The standard treatment for glioblastoma involves a combination of surgery, radiation and chemotherapy but have limited impact on survival. The exponential increase in targeted agents directed at pivotal oncogenic pathways now provide new therapeutic opportunities for this tumour type. However, lack of comprehensive precision oncology testing at diagnosis means such therapeutic opportunities are potentially overlooked.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!